Alkermes price target lowered to $44 from $45 at RBC Capital

RBC Capital lowered the firm’s price target on Alkermes (ALKS) to $44 from $45 and keeps an Outperform rating on the shares as part of the firm’s broader research note previewing Q1 results in Biotech. Seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in Q1 by weather impact, particularly for launching and in-clinic products, but the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable, the analyst tells investors in a research note.